Vontobel Asset Management Inc. decreased its stake in Celgene Corp. (NASDAQ:CELG) by 24.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,931,014 shares of the biopharmaceutical company’s stock after selling 635,105 shares during the period. Celgene Corp. makes up about 1.6% of Vontobel Asset Management Inc.’s holdings, making the stock its 23rd largest position. Vontobel Asset Management Inc. owned about 0.25% of Celgene Corp. worth $208,650,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jolley Asset Management LLC increased its position in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 450 shares during the last quarter. Smithfield Trust Co. increased its position in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares during the last quarter. Integrated Investment Consultants LLC increased its position in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 240 shares during the last quarter. Feltz Wealth PLAN Inc. purchased a new position in Celgene Corp. during the second quarter valued at $148,000. Finally, Integrated Wealth Management increased its position in Celgene Corp. by 2.5% in the second quarter. Integrated Wealth Management now owns 1,664 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 40 shares during the last quarter. Institutional investors own 77.85% of the company’s stock.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded up 0.17% during mid-day trading on Friday, hitting $121.06. The company had a trading volume of 1,792,549 shares. The company has a 50-day moving average price of $108.41 and a 200-day moving average price of $106.51. The company has a market capitalization of $93.85 billion, a price-to-earnings ratio of 45.98 and a beta of 1.71. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The company had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $2.84 billion. During the same quarter in the prior year, the firm earned $1.23 earnings per share. Celgene Corp.’s revenue was up 27.8% compared to the same quarter last year. On average, equities analysts anticipate that Celgene Corp. will post $5.92 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Vontobel Asset Management Inc. Decreases Stake in Celgene Corp. (CELG)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/27/vontobel-asset-management-inc-decreases-stake-in-celgene-corp-celg.html.

A number of analysts recently issued reports on the company. Argus reissued a “buy” rating and set a $155.00 price objective on shares of Celgene Corp. in a report on Wednesday, September 7th. Leerink Swann reaffirmed a “market perform” rating and issued a $135.00 price target on shares of Celgene Corp. in a report on Monday, September 12th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $138.00 price target on shares of Celgene Corp. in a report on Tuesday, August 2nd. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Celgene Corp. in a report on Tuesday, October 18th. Finally, Zacks Investment Research cut Celgene Corp. from a “buy” rating to a “hold” rating in a report on Monday, August 8th. Four equities research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $136.30.

In other Celgene Corp. news, Director Gilla Kaplan sold 9,710 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the sale, the director now owns 72,142 shares of the company’s stock, valued at approximately $7,678,794.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard W. Barker sold 20,000 shares of the stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $110.82, for a total value of $2,216,400.00. Following the sale, the director now directly owns 31,332 shares in the company, valued at approximately $3,472,212.24. The disclosure for this sale can be found here. 0.97% of the stock is owned by corporate insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.